Our people
Partner, Patent Attorney
Chemistry
London
UPC RepresentativeOur IP specialists work at all stages of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.
View the teamWe want to keep you up to date with developments in the IP world and let you know what we are up to at Mewburn Ellis.
Learn moreWe believe in making it easy for you to find the information that you want – and you can always contact us if you can’t find what you need
Read our law and practice guidesWilhelmus (Willum) deals with patent drafting, prosecution and opposition in all key jurisdictions. His particular area of focus is the pharmaceutical sector, where he has extensive experience working on small molecules for therapy of a range of indications, and spanning early drug discovery projects through to clinical candidates.
Areas of Expertise
Clients
Willum works with a broad range of clients – primarily in the UK, Europe, and the US. They include universities and spin-out companies, as well as large multinational pharmaceutical corporations.
Background
He has a BSc (Hons.) in chemistry from Queens University in Canada and a PhD in chemistry from the University of Cambridge, and subsequently held a post-doctoral fellowship at Stanford University in the US.
Willum joined Mewburn Ellis LLP in 1999, after working as a US patent agent for five years. He qualified as a Chartered Patent Attorney in 2004 and as a European Patent Attorney in 2005. He joined the partnership in 2005.
He has been a tutor at the Centre d’Études Internationales de la Propriété Intellectuelle (CEIPI) since 2004 and continues to lecture prospective European patent attorneys in Strasbourg on an annual basis.
Recommendations
Described as “very good at grasping and summarising problems in the chemistry field... He is also highly regarded for his work on pharmaceutical and polymer patents.”
Client feedback: “Thank you so much for everything you’ve done for the project so far. We couldn’t have got the compound to this stage without you”. UK based Drug Discovery Company